Tiziana gains on FDA clearance to start Alzheimer's treatment study

Tiziana Life Sciences

15/08/2023 16:17

** Drug developer Tiziana Life Sciences'  TLSA.O  shares
rise ~34% to $0.80
    ** Company says U.S. FDA has cleared the application to
begin trials for intranasal drug foralumab, which is being
studied as a treatment for Alzheimer's disease
    ** Stock up 36% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))